195 related articles for article (PubMed ID: 30145203)
1. Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
Jung JH; You S; Oh JW; Yoon J; Yeon A; Shahid M; Cho E; Sairam V; Park TD; Kim KP; Kim J
Cancer Lett; 2018 Nov; 437():1-12. PubMed ID: 30145203
[TBL] [Abstract][Full Text] [Related]
2. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X; Maity TK; Ross KE; Qi Y; Cultraro CM; Bahta M; Pitts S; Keswani M; Gao S; Nguyen KDP; Cowart J; Kirkali F; Wu C; Guha U
Cancer Res; 2021 Jun; 81(11):3051-3066. PubMed ID: 33727228
[TBL] [Abstract][Full Text] [Related]
3. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
4.
Shahid M; Kim M; Jin P; Zhou B; Wang Y; Yang W; You S; Kim J
Int J Biol Sci; 2020; 16(14):2490-2505. PubMed ID: 32792852
[TBL] [Abstract][Full Text] [Related]
5. Deep Phospho- and Phosphotyrosine Proteomics Identified Active Kinases and Phosphorylation Networks in Colorectal Cancer Cell Lines Resistant to Cetuximab.
Abe Y; Nagano M; Kuga T; Tada A; Isoyama J; Adachi J; Tomonaga T
Sci Rep; 2017 Sep; 7(1):10463. PubMed ID: 28874695
[TBL] [Abstract][Full Text] [Related]
6. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
[TBL] [Abstract][Full Text] [Related]
7. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
Krafft U; Tschirdewahn S; Hess J; Harke NN; Hadaschik B; Olah C; Krege S; Nyirády P; Szendröi A; Szücs M; Módos O; Székely E; Reis H; Szarvas T
Urol Oncol; 2019 Nov; 37(11):810.e7-810.e15. PubMed ID: 31053526
[TBL] [Abstract][Full Text] [Related]
8. CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
Gao D; Wang R; Gong Y; Yu X; Niu Q; Yang E; Fan G; Ma J; Chen C; Tao Y; Lu J; Wang Z
Free Radic Biol Med; 2023 Nov; 208():587-601. PubMed ID: 37726090
[TBL] [Abstract][Full Text] [Related]
9. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
[TBL] [Abstract][Full Text] [Related]
11. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
12. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
Liu Z; Wang Y; Yao Y; Fang Z; Miao QR; Ye M
J Proteomics; 2019 Sep; 208():103501. PubMed ID: 31454556
[TBL] [Abstract][Full Text] [Related]
14. Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis.
Taoka Y; Matsumoto K; Ohashi K; Minamida S; Hagiwara M; Nagi S; Saito T; Kodera Y; Iwamura M
Biomed Res; 2015; 36(4):253-61. PubMed ID: 26299484
[TBL] [Abstract][Full Text] [Related]
15. Adseverin: a novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis.
Miura N; Takemori N; Kikugawa T; Tanji N; Higashiyama S; Yokoyama M
Mol Oncol; 2012 Jun; 6(3):311-22. PubMed ID: 22265592
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells.
Kim HJ; Gong MK; Yoon CY; Kang J; Yun M; Cho NH; Rha SY; Choi YD
Yonsei Med J; 2020 Jul; 61(7):587-596. PubMed ID: 32608202
[TBL] [Abstract][Full Text] [Related]
17. Phosphoproteomics reveals network rewiring to a pro-adhesion state in annexin-1-deficient mammary epithelial cells.
Alli-Shaik A; Wee S; Lim LHK; Gunaratne J
Breast Cancer Res; 2017 Dec; 19(1):132. PubMed ID: 29233185
[TBL] [Abstract][Full Text] [Related]
18. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
Olsen JV; Vermeulen M; Santamaria A; Kumar C; Miller ML; Jensen LJ; Gnad F; Cox J; Jensen TS; Nigg EA; Brunak S; Mann M
Sci Signal; 2010 Jan; 3(104):ra3. PubMed ID: 20068231
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide Hydroxamic Acid Can Re-sensitize a Cisplatin-Resistant Human Bladder Cancer.
Ryu H; Jin H; Ho JN; Bae J; Lee E; Lee SE; Lee S
Biol Pharm Bull; 2019; 42(1):66-72. PubMed ID: 30606990
[TBL] [Abstract][Full Text] [Related]
20. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
